DR. JOHN GOGGIN, DPM PODIATRIST

Dr. Goggin is Board Certified in Foot Surgery by theAmerican Board of Foot and Ankle Surgery, and a Member of the American Podiatric Medical Association Vice president of theFlorida Podiatric Medical Association.

Education:

South Miami Hospital— Miami, Florida
Two year surgical residency
July 1997-June 1999

South Miami Hospital— Miami, Florida
Primary podiatric medical residency
July 1996 June 1997

Barry University— Miami Shores, Florida
Doctor of Podiatric Medicine ( D.P.M. )
August 1992 to May 1996

Publications:

Verrucus Carcinoma, A Case Presentation.
ACFAS scientific conference 2/02

Arthroscopy of the Ankle and Subtalar Joint.
Clin Podiatr Med Surg 2000
Jan;17(1):55-79, vi

Immunilogic Desentization to Imipenem
A Review of Protocol
Journal of the Florida Podiatric Medical Association
August 1998 p 1-5

Acral Lentiginous Melanoma,
J Foot Ankle Surg 1998 NovDec;37(6):5405

The Role of Combined Magnetic Field Bone Growth Stimulation as an Adjunct in the Treatment of Neuroarthropathy/Charcot Joint: an Expanded Pilot Study.
J Foot Ankle Surg 1998 NovDec;37(6):5105; discussion 5501

Clinical Research Experience:

• Genentec, VGF2763g, 2003-2005
  An Exploratory, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) For Induction of Healing Of Chronic, Diabetic Foot Ulcers

• Sub-Investigator – Dermacor, FN 01-02, 2003-2005
  A double-blind, placebo-controlled, phase II randomized study to assess, in Combination with high compression therapy, the safety and potential efficacy Of homologous human plasma fibronectin applied topically in a calcium-alginate Sponge-like disk without fibronectin (the placebo), in the treatment of chronic Venous ulcers of the lower limb

• Sub-Investigator – Novartis, CSF0327KUS14, 2003-2005
  A randomized, open label, multicenter trial to investigate the efficacy and safety Of 12 weeks oral terbinafine (250 mg qd) with and without nail debridement in The treatment of onychomycosis

• Sub-Investigator – Encelle, DFU-002, 2002-2004
  A Controlled, Randomized Pilot Study to Assess E-Matrix for the Treatment Of Diabetic Foot Ulcers

• Sub-Investigator – Celleration, Cell 02-01 Rev.A, 2002-2003
  A Comparative Prospective, Randomized, Double-Masked, Parallel Group, Controlled Trial of MUST Therapy Versus Sham Control When Added to Standard of Care in the Treatment of Diabetic Neuropathic Ulcers

• Sub-Investigator – Pharmacia, VALA-0513-144-P1, 2002-2003
  Multiple Dose Randomized Double Blind, Placebo Controlled study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients For the Treatment of Post-Surgical Pain from Bunion Surgery

• Sub-Investigator – ATS/Smith & Nephew, NBT DCT 99/03, 2002-2005
  A prospective, multi-center, randomized, controlled clinical investigation of Dermagraft in patients with venous leg ulcers.

• Sub-investigator – UCB Pharma, G01001, 2001-2002
  A Multi-Center, Double-Blind, Randomized, Parallel Group, two-period study to Evaluate the efficacy and safety of oral doses of an extended-release combination Of hydrocodone 15 mg and acetaminophen 1000mg (Lortab XR), extended Release hydrocodone 15 mg tablets, extended release acetominophen 1000 mg Tablets, and placebo in the treatment of moderate to severe pain in subjects under-Going orthopedic surgery

• Sub-investigator – Human Genome Sciences, KGF-2-WHO4, 2001-2003
  A Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Repifermin (KGF-2) in Subjects with Venous Ulcers.

• Sub-investigator – Bristol-Myers Squibb, AI464-026, 2000-2001
  A Randomized, Double-Blind, Multi-Center, Comparative Phase III Study of Oral Ciprofloxin/Metronidazole vs. Oral BMS-284756 in the Treatment of Complicated Skin and Skin Structure Infection

• Sub-investigator – UCB Pharma, GO1011, 2000
  A Multi-Center, Single-Dose, Double-Blind, Randomized, Parallel Group Pilot Study to Evaluate the Efficacy and Safety of Oral Doses of an Extended Release Combination of Hydrocodone 15 mg and Acetaminophen 1000 mg, and placebo in the treatment of moderate to severe post-surgical orthopedic pain

• Sub-investigator – NIH Sponsored, Peripheral Neuropathy Study, 2000
  Magnetic Stimulation in Diabetic Peripheral Neuropathy, Weintraub (PI)

• Sub-investigator – Advanced Tissue Sciences, Inc., DG-04-07-0798, 1998-2000
  A Prospective, Multicenter, Randomized, Single-Masked, Controlled, Clinical Investigation of Dermagraft in Patients with Plantar Diabetic Foot Ulcer

DR. JOHN V. PERRONE, DPM PODIATRIST

Dr. Perrone is is Board Certified in Foot Surgery by the American Board of Foot and Ankle Surgery, and a Member of the American Podiatric Medical Association and the Florida Podiatric Medical Association.

Education:

South Miami Hospital– Miami, Florida
Two year surgical residency
July 2001-June 2003

South Miami Hospital– Miami, Florida
Primary podiatric medical residency
July 2000 June 2001

Barry University– Miami Shores, Florida
Doctor of Podiatric Medicine ( D.P.M. )
August 1995 to May 2000

Publications and Research Experience

Hanft J, Surprenant M, Goggin J, Linn D, Perrone JV, Warren W, Temar K
A pilot study examining effectiveness of plain radiographic techniques in assessing bone healing following 1st metatarsal osteotomy with internal fixation ACFAS research grant 3/02, submitted for publication.

Cohen DA, Perrone JV, Temar K
Differential Diagnosis of Distal Symmetrical Sensory Poyneuropathy
Foot and Ankle Quarterly 14(4)

Goggin J, Linn D, Perrone JV
Verrucus Carcinoma, A Case Presentation.
ACFAS scientific conference 2/02

UCB Pharma Post-operative Pain Control Phase 3 Clinical Trials.
Research Assistant 7/01-5/02

Advanced Tissue Sciences/Dermagraft Venous Phase 2 Clinical Trials.
Research Assistant 7/00-7/01

Human Genomic Science/HGS WHO4 Repifermin Phase 2 Clinical Trials.
Research Assistant 7/00-7/01